Posted by Michael Wonder on 14 Feb 2024
Rocket Pharmaceuticals announces update on FDA review timeline of Kresladi (marnetegragene autotemcel) for the treatment of severe leukocyte adhesion deficiency-I
13 February 2024 - New Prescription Drug User Fee Act date of 30 June 2024.
Rocket Pharmaceuticals today announced the US FDA has extended the priority review period for the biologics license application for Kresladi (marnetegragene autotemcel) for severe leukocyte adhesion deficiency-I.
